Source link : https://www.newshealth.biz/health-news/retifanlimab-chemo-combo-boosts-pfs-in-advanced-squamous-cell-anal-cancer/
Combining retifanlimab (Zynyz) with standard-of-care chemotherapy significantly improved progression-free survival (PFS) in treatment-naïve patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC), according to phase III trial results. PFS was 9.3 months for patients treated with the anti-PD-1 monoclonal antibody versus 7.4 months for those treated with placebo and chemotherapy […]
Author : News Health
Publish date : 2024-09-15 14:26:23
Copyright for syndicated content belongs to the linked Source.